# Bristol-Myers Squibb clinical trials: 1,562 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,562 trials with Bristol-Myers Squibb as lead sponsor, 115 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bristol-Myers Squibb: 1,562 rows for $78.10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 5 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,562
- Recruiting or not yet: 115
- Read on: November 19, 2026

## Trials

The 25 newest of 1,562, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07940777 | A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy... | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Non-obstructive Hypertrophic Cardiomyopathy | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940777) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| October 21, 2026 | NCT07887763 | A Phase 1 Study to Evaluate Safety, Tolerability, and Drug Levels of BMS-986485 in Healthy Adult Participants | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Healthy Volunteers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887763) |
| October 14, 2026 | NCT07873931 | A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies, Systemic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873931) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 1, 2026 | NCT07852962 | Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants. | Bristol-Myers Squibb | Phase 1 | Not yet recruiting | Healthy Volunteers | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852962) |
| October 1, 2026 | NCT07852884 | First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Bristol-Myers Squibb | Observational | Active not recruiting | Renal Cell Carcinoma (RCC) | 1,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852884) |
| September 29, 2026 | NCT07846059 | Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | Bristol-Myers Squibb | Observational | Not yet recruiting | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846059) |
| September 2, 2026 | NCT07800897 | A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants | Bristol-Myers Squibb | Phase 1 | Recruiting | Healthy Female Adults | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07800897) |
| August 27, 2026 | NCT07791199 | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis | 2,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791199) |
| August 24, 2026 | NCT07783373 | Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia | Bristol-Myers Squibb | Observational | Active not recruiting | Schizophrenia | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783373) |
| August 21, 2026 | NCT07780383 | A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in... | Bristol-Myers Squibb | Phase 1 | Recruiting | Alzheimer's Disease, Healthy Participants | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780383) |
| August 20, 2026 | NCT07777133 | A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of \[14C\]Navlimetostat (BMS-986504) in Healthy... | Bristol-Myers Squibb | Phase 1 | Recruiting | Healthy Female Participants | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777133) |
| August 20, 2026 | NCT07777120 | Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma | Bristol-Myers Squibb | Observational | Active not recruiting | Marginal Zone Lymphoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777120) |
| August 19, 2026 | NCT07772531 | A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder | Bristol-Myers Squibb | Phase 2 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07772531) |
| August 13, 2026 | NCT07763418 | A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease... | Bristol-Myers Squibb | Phase 1 | Recruiting | Kidney Failure, Chronic | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763418) |
| August 10, 2026 | NCT07755826 | Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan | Bristol-Myers Squibb | Observational | Recruiting | NTRK Fusion-positive Solid Tumors | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755826) |
| August 7, 2026 | NCT07752121 | First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms | Bristol-Myers Squibb | Observational | Recruiting | Myelodysplastic Neoplasms | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752121) |
| July 29, 2026 | NCT07732907 | Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia | Bristol-Myers Squibb | Observational | Recruiting | Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732907) |
| July 23, 2026 | NCT07722507 | Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis | Bristol-Myers Squibb | Observational | Not yet recruiting | Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722507) |
| July 21, 2026 | NCT07718139 | Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and... | Bristol-Myers Squibb | Observational | Active not recruiting | Non-Small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718139) |
| July 7, 2026 | NCT07689006 | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens | Bristol-Myers Squibb | Observational | Completed | Relapsed/Refractory Multiple Myeloma | 341 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689006) |
| July 2, 2026 | NCT07681440 | A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia | Bristol-Myers Squibb | Observational | Terminated | Myelodysplastic Syndromes, Beta-thalassemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681440) |
| July 2, 2026 | NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination... | Bristol-Myers Squibb | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680790) |
| July 2, 2026 | NCT07680764 | A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy... | Bristol-Myers Squibb | Phase 2 | Recruiting | Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680764) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 484 |
| Phase 1/2 | 105 |
| Phase 2 | 278 |
| Phase 2/3 | 25 |
| Phase 3 | 258 |
| Phase 4 | 51 |
| Not applicable | 50 |
| Observational | 310 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 1,159 |
| Terminated | 130 |
| Recruiting | 103 |
| Active not recruiting | 72 |
| Withdrawn | 58 |
| No longer available | 21 |
| Not yet recruiting | 12 |
| Available | 4 |
| Approved for marketing | 2 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Melanoma | 90 |
| Arthritis, Rheumatoid | 88 |
| Carcinoma, Non-Small-Cell Lung | 87 |
| Hepatitis C | 76 |
| HIV Infections | 75 |
| Neoplasms | 71 |
| Multiple Myeloma | 36 |
| Psoriasis | 31 |
| Carcinoma, Renal Cell | 31 |
| Acquired Immunodeficiency Syndrome | 29 |
| Cardiomyopathy, Hypertrophic | 26 |
| Hepatitis B, Chronic | 24 |
| Lung Neoplasms | 24 |
| Heart Failure | 23 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 23 |
| Atrial Fibrillation | 23 |
| Alzheimer Disease | 21 |
| Neoplasm Metastasis | 21 |
| Colorectal Neoplasms | 20 |
| Breast Neoplasms | 20 |
| Thrombosis | 19 |
| Diabetes Mellitus, Type 2 | 19 |
| Recurrence | 17 |
| Colitis, Ulcerative | 17 |
| Leukemia | 16 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
- [Lodges in the United States](https://specstream.ai/data/businesses/lodges/united-states)
- [Vending machine suppliers in the United States](https://specstream.ai/data/businesses/vending-machine-suppliers/united-states)
- [Endocrinology practices in the United States](https://specstream.ai/data/businesses/endocrinology-practices/united-states)
